- ¥125bn
- ¥112bn
- ¥26bn
- 50
- 30
- 38
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.25 | ||
| PEG Ratio (f) | 0.51 | ||
| EPS Growth (f) | 35.14% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.39 | ||
| Price to Tang. Book | 10.18 | ||
| Price to Free Cashflow | 51.17 | ||
| Price to Sales | 5.28 | ||
| EV to EBITDA | 11.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.18% | ||
| Return on Equity | 22.62% | ||
| Operating Margin | 39.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 7,446.07 | 9,773.86 | 12,690.25 | 17,418.97 | 26,010.57 | 32,450 | 49,087 | 38.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +626.02 | -45.25 | -62.3 | +717.23 | +309.72 | +8.43 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Directors
- Ying Luo CEO (55)
- Joseph Meyer CFO
- Thomas Eastling DRC (65)
- Takashi Kataoka DRC (77)
- Sadayuki Yasukawa DRC (66)
- Wanshou Guo IND (61)
- Hideaki Sashiwa IND (63)
- Liwen Wu IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 20th, 2001
- Public Since
- August 31st, 2007
- No. of Shareholders
- 13,762
- No. of Employees
- 843
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 50,059,717
- Address
- 3F, Nihonbashi-Honcho YS Bldg, CHUO-KU, 103-0023
- Web
- https://www.gnipharma.com/
- Phone
- +81 362143600
- Auditors
- Grant Thornton Taiyo LLC
Upcoming Events for 2160
Dividend For 2160.T - 0.0000 JPY
Similar to 2160
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the GNI share price?
As of Today at 21:21 UTC, shares in GNI are trading at ¥2,495. This share price information is delayed by 15 minutes.
How has the GNI share price performed this year?
Shares in GNI last closed at ¥2,495 and the price had moved by +13.77% over the past 365 days. In terms of relative price strength the GNI share price has outperformed the Nikkei 225 Index by +3.39% over the past year.
What are the analyst and broker recommendations for GNI?
The overall consensus recommendation for GNI is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the GNI dividend yield?
GNI does not currently pay a dividend.
Does GNI pay a dividend?
GNI does not currently pay a dividend.
When does GNI next pay dividends?
GNI does not currently pay a dividend.
How do I buy GNI shares?
To buy shares in GNI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GNI?
As of the previous close price of ¥2,495, shares in GNI had a market capitalisation of ¥125bn.
Where are GNI shares listed?
Here are the trading details for GNI:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 2160
What kind of share is GNI?
Based on an overall assessment of its quality, value and momentum GNI is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GNI share price forecast for 2024?
The analyst consensus target price for shares in GNI is ¥3,700. That is 48.3% above the last closing price of ¥2,495.
Analysts covering GNI currently have a consensus Earnings Per Share (EPS) forecast of ¥178 for the next financial year.
Find out moreWhat is the trend in the GNI share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GNI. Over the past six months, its share price has underperformed the Nikkei 225 Index by -4.89%.
As of the last closing price of ¥2,495, shares in GNI were trading -4.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GNI PE Ratio?
The GNI PE ratio based on its reported earnings over the past 12 months is 13.25. The shares last closed at ¥2,495.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GNI?
GNI's management team is headed by:
- Ying Luo - CEO
- Joseph Meyer - CFO
- Thomas Eastling - DRC
- Takashi Kataoka - DRC
- Sadayuki Yasukawa - DRC
- Wanshou Guo - IND
- Hideaki Sashiwa - IND
- Liwen Wu - IND